These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
762 related items for PubMed ID: 25459643
1. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation. Zilberberg J, Feinman R, Korngold R. Biol Blood Marrow Transplant; 2015 Jun; 21(6):1000-7. PubMed ID: 25459643 [Abstract] [Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL. Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [Abstract] [Full Text] [Related]
3. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease. Anderson LD, Mori S, Mann S, Savary CA, Mullen CA. Cancer Res; 2000 Oct 15; 60(20):5797-802. PubMed ID: 11059776 [Abstract] [Full Text] [Related]
4. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation. Rezvani AR, Storb RF. J Autoimmun; 2008 May 15; 30(3):172-9. PubMed ID: 18242060 [Abstract] [Full Text] [Related]
9. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond. Tsirigotis P, Shimoni A, Nagler A. Ann Med; 2014 Sep 15; 46(6):384-96. PubMed ID: 24888385 [Abstract] [Full Text] [Related]
10. Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy. Goulmy E. Cancer J; 2004 Sep 15; 10(1):1-7. PubMed ID: 15000488 [Abstract] [Full Text] [Related]
11. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways. Zimmerman Z, Shatry A, Deyev V, Podack E, Mammolenti M, Blazar BR, Yagita H, Levy RB. Biol Blood Marrow Transplant; 2005 Aug 15; 11(8):576-86. PubMed ID: 16041307 [Abstract] [Full Text] [Related]
14. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II. van Balen P, van Bergen CAM, van Luxemburg-Heijs SAP, de Klerk W, van Egmond EHM, Veld SAJ, Halkes CJM, Zwaginga JJ, Griffioen M, Jedema I, Falkenburg JHF. Front Immunol; 2018 Aug 15; 9():3016. PubMed ID: 30619360 [Abstract] [Full Text] [Related]
15. [Modification of Cytotoxic Lymphocytes with T Cell Receptor Specific for Minor Histocompatibility Antigen ACC-1Y]. Pilunov AM, Kuchmiy AA, Sheetikov SA, Filkin SY, Romaniuk DS, Rosov FN, Efimov GA. Mol Biol (Mosk); 2019 Aug 15; 53(3):456-466. PubMed ID: 31184611 [Abstract] [Full Text] [Related]
19. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine. Anderson LD, Petropoulos D, Everse LA, Mullen CA. Cancer Res; 1999 Apr 01; 59(7):1525-30. PubMed ID: 10197624 [Abstract] [Full Text] [Related]
20. Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma. van der Voort R, Volman TJ, Verweij V, Linssen PC, Maas F, Hebeda KM, Dolstra H. Biol Blood Marrow Transplant; 2013 Mar 01; 19(3):378-86. PubMed ID: 23266741 [Abstract] [Full Text] [Related] Page: [Next] [New Search]